Biogen to acquire Pfizer’s schizophrenia drug for up to $590m

This article was originally published here

Biogen has agreed to buy Pfizer’s investigational schizophrenia drug, PF-04958242, in a deal worth about $590m.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply